Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants

David I. Bernstein, David Allen Sack, Keith Reisinger, Edward Rothstein, Richard L. Ward

Research output: Contribution to journalArticle

Abstract

Rotavirus vaccine development is a high priority. The association between the tetravalent rhesus-human reassortant rotavirus vaccine and intussusception has increased the need to develop new vaccines. In a small efficacy trial, the human rotavirus vaccine 89-12 recently has been shown to be safe and effective; 184 of the 215 healthy infants initially enrolled in this trial were followed for a second year. Vaccine efficacy during the second year was 59% (P = .047). For the 2 years of observation, vaccine efficacy was 76% against rotavirus gastroenteritis, 83% against severe rotavirus gastroenteritis, and 100% against rotavirus illnesses requiring medical intervention (P <.001 for each). These encouraging results have led to continued evaluation, in several countries, of a vaccine candidate derived from strain 89-12.

Original languageEnglish (US)
Pages (from-to)1487-1489
Number of pages3
JournalJournal of Infectious Diseases
Volume186
Issue number10
DOIs
StatePublished - Nov 15 2002

Fingerprint

Rotavirus
Vaccines
Rotavirus Vaccines
Gastroenteritis
Intussusception
Observation
rotavirus vaccine 89-12

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. / Bernstein, David I.; Sack, David Allen; Reisinger, Keith; Rothstein, Edward; Ward, Richard L.

In: Journal of Infectious Diseases, Vol. 186, No. 10, 15.11.2002, p. 1487-1489.

Research output: Contribution to journalArticle

Bernstein, David I. ; Sack, David Allen ; Reisinger, Keith ; Rothstein, Edward ; Ward, Richard L. / Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. In: Journal of Infectious Diseases. 2002 ; Vol. 186, No. 10. pp. 1487-1489.
@article{1cdc8a0567b2432da303c3b01a0eddf1,
title = "Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants",
abstract = "Rotavirus vaccine development is a high priority. The association between the tetravalent rhesus-human reassortant rotavirus vaccine and intussusception has increased the need to develop new vaccines. In a small efficacy trial, the human rotavirus vaccine 89-12 recently has been shown to be safe and effective; 184 of the 215 healthy infants initially enrolled in this trial were followed for a second year. Vaccine efficacy during the second year was 59{\%} (P = .047). For the 2 years of observation, vaccine efficacy was 76{\%} against rotavirus gastroenteritis, 83{\%} against severe rotavirus gastroenteritis, and 100{\%} against rotavirus illnesses requiring medical intervention (P <.001 for each). These encouraging results have led to continued evaluation, in several countries, of a vaccine candidate derived from strain 89-12.",
author = "Bernstein, {David I.} and Sack, {David Allen} and Keith Reisinger and Edward Rothstein and Ward, {Richard L.}",
year = "2002",
month = "11",
day = "15",
doi = "10.1086/344732",
language = "English (US)",
volume = "186",
pages = "1487--1489",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants

AU - Bernstein, David I.

AU - Sack, David Allen

AU - Reisinger, Keith

AU - Rothstein, Edward

AU - Ward, Richard L.

PY - 2002/11/15

Y1 - 2002/11/15

N2 - Rotavirus vaccine development is a high priority. The association between the tetravalent rhesus-human reassortant rotavirus vaccine and intussusception has increased the need to develop new vaccines. In a small efficacy trial, the human rotavirus vaccine 89-12 recently has been shown to be safe and effective; 184 of the 215 healthy infants initially enrolled in this trial were followed for a second year. Vaccine efficacy during the second year was 59% (P = .047). For the 2 years of observation, vaccine efficacy was 76% against rotavirus gastroenteritis, 83% against severe rotavirus gastroenteritis, and 100% against rotavirus illnesses requiring medical intervention (P <.001 for each). These encouraging results have led to continued evaluation, in several countries, of a vaccine candidate derived from strain 89-12.

AB - Rotavirus vaccine development is a high priority. The association between the tetravalent rhesus-human reassortant rotavirus vaccine and intussusception has increased the need to develop new vaccines. In a small efficacy trial, the human rotavirus vaccine 89-12 recently has been shown to be safe and effective; 184 of the 215 healthy infants initially enrolled in this trial were followed for a second year. Vaccine efficacy during the second year was 59% (P = .047). For the 2 years of observation, vaccine efficacy was 76% against rotavirus gastroenteritis, 83% against severe rotavirus gastroenteritis, and 100% against rotavirus illnesses requiring medical intervention (P <.001 for each). These encouraging results have led to continued evaluation, in several countries, of a vaccine candidate derived from strain 89-12.

UR - http://www.scopus.com/inward/record.url?scp=0037111031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037111031&partnerID=8YFLogxK

U2 - 10.1086/344732

DO - 10.1086/344732

M3 - Article

C2 - 12404166

AN - SCOPUS:0037111031

VL - 186

SP - 1487

EP - 1489

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 10

ER -